Making Virus Inactivation a Reality for Continuous Upscaled Processes
The Cadence™ Virus Inactivation (VI) system, a fully automated low pH virus inactivation system for both batch and continuous processing is one of the latest additions to Pall’s Continuous platform. This webinar will discuss how traditional low pH virus inactivation has been translated into an automatic system, and also the additional challenges associated with making it a continuous process. There will be a review of the two methods used for validating the design and an overview of the integration of capture chromatography and virus inactivation, which represents the first commercial scale combined unit operations in this space.

Moderator


David Johnson
Senior Global Product Manager, Continuous Purification
Pall Biotech

Speakers


Mark Schofield, Ph.D.
Principal R&D Engineer
Pall Biotech
Making Virus Inactivation a Reality for Continuous Upscaled Processes

Download our eBook on Virus Safety
Biotech | Pall Corporation webinar series
In 2019 Swissfillon were inspected and approved by the FDA to supply drug products into the USA, following on from EU approval in 2018. This young fill finish CMO was started in Switzerland in 2013 and built a state-of-the-art cGMP production facility from the ground up.
Swissfillon recognized early on that single-use systems met their requirements for multi-product manufacturing and would help their clients get their drugs to market faster.
During this case-study webinar, participants will learn:
- How working in partnership with a supplier can be part of a QbD approach to minimize risk
- Strategies & design improvements for single-use systems to reduce risk in the process
- How a shadowboard can be used to make single-use system leak tests, PUPSIT and the filtration process fast, safe and simple